Related Posts
13Sep
Privo receives Commercialization Award from the National Cancer Institute
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston... read more
24Oct
Privo Technologies begins FDA Approved Clinical Trials
BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer... read more
07Sep
FDA Grants $2 million award to Privo Technologies to expedite its clinical trial
Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development... read more
10Dec
Privo Technologies receives 2015 TechConnect Innovation Award
Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was... read more
07Oct
BioNetwork Partnering Summit
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more
01Jan
Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.
The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support... read more
10Jan
Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions... read more
01Aug
Privo receives a $220,000 Award from the National Institute of Dental and Craniofacial Research (NIDCR)
Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more
30Jun
Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the... read more
03Nov
Privo receives Orphan Designation from the Food and Drug Administration.
Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future... read more
- © Web Design & Development
- © UX Strategy & Digital Branding
